

Chunkit Fung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6885528/publications.pdf>

Version: 2024-02-01

89
papers

1,758
citations

304602

22
h-index

289141

40
g-index

89
all docs

89
docs citations

89
times ranked

2321
citing authors

#	ARTICLE	IF	CITATIONS
1	Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. <i>Ear and Hearing</i> , 2022, 43, 794-807.	1.0	13
2	Re: Thyroid hypofunction in aging testicular cancer survivors. <i>Acta Oncologica</i> , 2022, 61, 386-387.	0.8	1
3	Increased risk of high-grade prostate cancer among testicular cancer survivors. <i>PLoS ONE</i> , 2022, 17, e0263573.	1.1	0
4	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. <i>Cancer Medicine</i> , 2022, 11, 2801-2816.	1.3	14
5	Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS). <i>Journal of Clinical Oncology</i> , 2022, 40, 12080-12080.	0.8	0
6	Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors. <i>Journal of Clinical Oncology</i> , 2022, 40, e24089-e24089.	0.8	0
7	Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, e24066-e24066.	0.8	0
8	Impact of cisplatin-induced hearing loss (CIHL) on patient-reported social and emotional functioning. <i>Journal of Clinical Oncology</i> , 2022, 40, 12120-12120.	0.8	0
9	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4618-TPS4618.	0.8	1
10	Surviving Testicular Cancer: The Role of the Contralateral Testicle. <i>Journal of Clinical Oncology</i> , 2021, 39, 265-268.	0.8	3
11	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1129-1138.	1.1	4
12	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy. <i>Journal of Clinical Oncology</i> , 2021, 39, 12004-12004.	0.8	0
13	Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments. <i>Journal of Clinical Oncology</i> , 2021, 39, 5016-5016.	0.8	1
14	Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels. <i>Journal of Clinical Oncology</i> , 2021, 39, 12063-12063.	0.8	1
15	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4591-TPS4591.	0.8	0
16	Identifying gaps in the coverage of survivorship care services. <i>Journal of Clinical Oncology</i> , 2021, 39, 6583-6583.	0.8	1
17	Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 5025-5025.	0.8	2
18	Testicular Cancer Survivorship: Looking Back to Move Forward. <i>Journal of Clinical Oncology</i> , 2021, 39, 3531-3534.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms. <i>Cardio-Oncology</i> , 2021, 7, 34.	0.8	4
20	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa022.	1.4	11
21	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24â€‰%900 Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa017.	1.4	12
22	Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1497-1498.	0.8	0
23	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Womenâ€™s Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 747-757.	1.1	16
24	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , 2020, 26, 6550-6558.	3.2	9
25	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5913-5924.	3.2	16
26	Effects of a Homeâ€¢based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1005-1011.	1.3	37
27	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	3.2	27
28	Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial. <i>Supportive Care in Cancer</i> , 2019, 27, 4615-4625.	1.0	38
29	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Oncologist</i> , 2019, 24, 688-690.	1.9	15
30	Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2019, 27, 7-8.	1.0	3
31	Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11507-11507.	0.8	2
32	Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet need.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11625-11625.	0.8	1
33	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 459-468.	2.3	13
34	Testicular Cancer Survivorship. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1557-1568.	2.3	42
35	Genetic testing patterns for homologous recombination repair (HRR) alterations in patients with metastatic prostate cancer (mPC): An assessment at the University of Rochester (UR).. <i>Journal of Clinical Oncology</i> , 2019, 37, 322-322.	0.8	0
36	Impact of cisplatin-related hearing loss (HL) and tinnitus on patient functioning.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23085-e23085.	0.8	0

#	ARTICLE	IF	CITATIONS
37	A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naïve systemic prostate cancer (HNSPCa): Tolerability and geriatric assessment (GA) results.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16518-e16518.	0.8	0
38	Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11573-11573.	0.8	1
39	The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11590-11590.	0.8	2
40	Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16058-e16058.	0.8	0
41	Yoga for the Management of Cancer Treatment-Related Toxicities. <i>Current Oncology Reports</i> , 2018, 20, 5.	1.8	35
42	Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1019-1028.	1.0	208
43	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e761-e769.	0.9	28
44	A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1180-1187.	0.6	15
45	Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1505-1512.	0.8	95
46	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.2	0
47	Risk of solid cancer after chemotherapy. <i>Nature Reviews Urology</i> , 2018, 15, 660-661.	1.9	2
48	Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. <i>Advances in Urology</i> , 2018, 2018, 1-20.	0.6	81
49	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 257-265.	2.3	24
50	A systematic review of randomized controlled trials (RCTs) of exercise interventions using digital activity trackers (E-DAT) in cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	0.8	1
51	Exercise for Toxicity Management in Cancer—A Narrative Review. <i>Oncology & Hematology Review</i> , 2018, 14, 28.	0.2	24
52	Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10058-10058.	0.8	0
53	Pretreatment physical activity to predict short- and long-term chemotherapy-induced peripheral neuropathy (CIPN) in a nationwide longitudinal study of paclitaxel for breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10018-10018.	0.8	0
54	Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4545-4545.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Exercise for Toxicity Management in Cancer-A Narrative Review. <i>Oncology & Hematology Review</i> , 2018, 14, 28-37.	0.2	31
56	Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. <i>Clinical Cancer Research</i> , 2017, 23, 3325-3333.	3.2	65
57	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5757-5768.	3.2	63
58	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1211-1222.	0.8	86
59	Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10075-10075.	0.8	1
60	A phase II RCT of high-dose vitamin D supplementation for androgen deprivation therapy (ADT)-induced bone loss among older prostate cancer (PCa) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10113-10113.	0.8	1
61	Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA10012-LBA10012.	0.8	1
62	Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA10012-LBA10012.	0.8	5
63	An integrative approach to personalized cancer survivorship care at an academic medical center.. <i>Journal of Clinical Oncology</i> , 2017, 35, 37-37.	0.8	0
64	Effect of exercise on quality of life (QoL) in 198 older patients with cancer: A URCC NCORP nationwide RCT.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10019-10019.	0.8	3
65	Genome-wide association study (GWAS) of chemotherapy-induced Raynaud's phenomenon (RP) to reveal shared pathways with cardiovascular disease (CVD).. <i>Journal of Clinical Oncology</i> , 2017, 35, e18162-e18162.	0.8	0
66	Effects of exercise on dyspnea and cancer-related fatigue in patients with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16580-e16580.	0.8	0
67	Feasibility of utilizing a novel mhealth platform to deliver an evidence-based exercise intervention among testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, e21608-e21608.	0.8	0
68	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2712-2720.	0.8	197
69	Association of falls with health-related quality of life (HRQOL) in older cancer survivors: A population based study. <i>Journal of Geriatric Oncology</i> , 2016, 7, 201-210.	0.5	32
70	Treatment of Metastatic Prostate Cancer in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 63.	1.8	6
71	Reply to S. Alanee et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1285-1286.	0.8	0
72	Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10015-10015.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Long-term Morbidity of Testicular Cancer Treatment. <i>Urologic Clinics of North America</i> , 2015, 42, 393-408.	0.8	50
74	Secondary malignant neoplasms in testicular cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 392-398.	0.8	34
75	Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3105-3115.	0.8	107
76	Comprehensive characterization of cisplatin-related hearing loss in U.S. and Canadian Testicular Cancer Survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9570-9570.	0.8	2
77	Association of falls with health related quality of life (HRQOL) in older cancer patients: A population based longitudinal study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20524-e20524.	0.8	1
78	Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 438-438.	0.8	0
79	Cardiovascular disease (CVD) risk factors among cisplatin-treated testicular cancer survivors (TCS): A multicenter clinical study of U.S. and Canadian patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 391-391.	0.8	1
80	Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9519-9519.	0.8	2
81	A Case Series of Transformation of Teratoma to Primitive Neuroectodermal Tumor: Evolving Management of a Rare Malignancy. <i>Rare Tumors</i> , 2014, 6, 18-21.	0.3	10
82	Impact of Bladder Cancer on Health Related Quality of Life in 1,476 Older Americans: A Cross-Sectional Study. <i>Journal of Urology</i> , 2014, 192, 690-695.	0.2	42
83	Reply to G. Gandaglia et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1167-1169.	0.8	0
84	Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. <i>Fertility and Sterility</i> , 2014, 102, 808-815.e1.	0.5	53
85	Changes in health-related quality of life (HRQL) after bladder cancer (BC) diagnosis (DX): A longitudinal population-based study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 317-317.	0.8	0
86	Cardiovascular mortality (CVM) among testicular nonseminoma (TN) survivors after chemotherapy (CHEM) or surgery (SURG).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9593-9593.	0.8	0
87	Solid Tumors After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3807-3814.	0.8	122
88	Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB).. <i>Journal of Clinical Oncology</i> , 2013, 31, 226-226.	0.8	1
89	Second Malignant Neoplasms in Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 545-556.	2.3	36